In just over a month, the Georgia World Congress Center in Atlanta will host the American Association for Cancer Research (AACR) Annual Meeting 2019. This signature event showcases the latest and most promising developments in cancer research, drawing scientists, clinicians, advocates, and policymakers from around the world.Read More
There has been a rapid expansion of technology in recent years, from artificial intelligence to intensive genetic sequencing to wearable trackers of fitness and health. How all of this technology can be effectively incorporated into population sciences research is an area of active inquiry.
To facilitate discussion and showcase research in this area, the American Association for Cancer Research (AACR) is hosting a conference, Modernizing Population Sciences in the Digital Age, in San Diego from Feb. 19-22. This four-day meeting will include discussions about the best use of mobile technology, how to best leverage large datasets, and how to incorporate modern technologies into existing and upcoming studies.Read More
The American Association for Cancer Research (AACR) Annual Meeting 2019 will soon be upon us. It begins in the Georgia World Congress Center, Atlanta, at 3 p.m. on Friday, March 29. The Friday start, which is a day earlier than usual, is to ensure that meeting attendees have the maximal ability to participate in the expanded slate of educational sessions and methods workshops included in this year’s program. The content of these and the other AACR Annual Meeting 2019 sessions can be viewed through the Online Itinerary Planner starting later today.Read More
The 41st San Antonio Breast Cancer Symposium, held Dec. 4-8, drew more than 7,500 attendees from more than 90 countries. The Symposium offered the latest clinical, translational, and basic research, providing a forum for interaction and communication among researchers, health professionals, and those with a special interest in breast cancer.Read More
Radiotherapy is a mainstay of cancer treatment. In recent years, improved technology has allowed many cancer patients to receive more targeted doses of radiation, which can improve efficacy and spare …Read More
Pancreatic cancer remains a challenging disease to treat, with a five-year survival rate of less than 9 percent, according to recent statistics. Unlike many other cancers, which can now be treated with checkpoint blockade immunotherapy, pancreatic cancer often does not respond to this type of treatment. One potential reason for this lack of efficacy is that pancreatic tumors tend to be nonimmunogenic, meaning that the cancer fails to elicit a strong immune response.Read More
The human microbiome – the collection of bacteria, viruses, fungi, and other microorganisms that live inside and on the surface of our bodies – has garnered significant scientific interest in recent years. The Human Microbiome Project (HMP), which was launched in 2007, seeks to characterize the diverse microbiota to help understand how these microbes impact human health and disease. Initial results from the HMP predict that over 10,000 microbial species coexist within the human ecosystem.Read More
When Michael Lawing was diagnosed with stage 3 renal cell carcinoma in 1997, he knew almost nothing about the disease.
Neither did his local urologist in rural North Carolina.
Within three years, Lawing’s cancer metastasized. His local doctor referred him to a specialist in Charlotte. Under his care, Lawing began a clinical trial of an immunotherapeutic drug. His cancer stabilized. Over the past two decades, he has experienced several recurrences of cancer, but a steady stream of newly approved treatments, most recently the immunotherapeutic Opdivo (nivolumab), have kept his disease under control. He is currently monitored with quarterly CT scans, but is taking no additional medication and experiences no symptoms or side effects.Read More
In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.Read More
The 30th Anniversary AACR Special Conference Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer is focusing on a relatively new interdisciplinary field that seeks to further cancer research through the use of mathematics and computation, among other disciplines.
We had the opportunity to speak with both co-chairs about convergence and several areas of interest that will be discussed at the upcoming meeting, to be held Oct. 14-17 in Newport, Rhode Island.Read More